Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673248 | 1.00 | AAK1 (0.43) | AAK1LMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL29539178 | 0.84 | HDAC1 (0.42) | AAK1LMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL8200994 | 0.84 | HDAC1 (0.42) | AAK1LMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL16722382 | 0.80 | AAK1 (0.42) | AAK1MAPK1HDAC3HDAC1EGFR | |
| SCHEMBL16722381 | 0.80 | AAK1 (0.42) | AAK1MAPK1HDAC3HDAC1EGFR | |
| SCHEMBL10037124 | 0.78 | SIGMAR1 (0.45) | LMNAHTTSMN1; SMN2MAPK1IDO1 | |
| SCHEMBL3634659 | 0.78 | TDP1 (0.48) | SMN1; SMN2IDO1MAPTKDM4EALDH1A1 | |
| SCHEMBL956895 | 0.77 | PRKCI (0.50) | AAK1MAPK1HDAC3HDAC1EGFR | |
| SCHEMBL4003622 | 0.77 | AAK1 (0.41) | AAK1MAPK1HDAC3HDAC1MAPK13 | |
| SCHEMBL8776014 | 0.76 | CYP3A4 (0.47) | LMNAHTTSMN1; SMN2MAPK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4025211-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | Trevena, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114585360-A | Methods of using the same for the treatment of epilepsy | 特维娜有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2018231745-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| US-20160362382-A1 | BENZAMIDE DERIVATIVES | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2016-12-15 | — | — | US | disclosed |
| US-9464059-B2 | Benzamide derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20150284336-A1 | BENZAMIDE DERIVATIVES | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2015-10-08 | — | — | US | disclosed |
| US-9125901-B2 | 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-2445345-B1 | BENZAMIDE DERIVATIVES | TRANSLATIONAL GENOMICS RES INST (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20120142922-A1 | BENZAMIDE DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | AAK1 1257/4885LMNA 2749/4885HTT 3156/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | AAK1 1815/4885LMNA 2217/4885HTT 3284/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | AAK1 3029/4885LMNA 1297/4885HTT 1455/4885 |
| US-20120142922-A1 | BENZAMIDE DERIVATIVES | BRDT, BRD3, BRD2 | AAK1 4280/4885LMNA 1502/4885HTT 3502/4885 |
| US-20150284336-A1 | BENZAMIDE DERIVATIVES | BRDT, BRD3, BRD2 | AAK1 4280/4885LMNA 1502/4885HTT 3502/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | AAK1 1257/4885LMNA 2749/4885HTT 3156/4885 |
| US-20160362382-A1 | BENZAMIDE DERIVATIVES | BRDT, BRD3, BRD2 | AAK1 4280/4885LMNA 1502/4885HTT 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.